Similar to our findings here, Bristol-Meyers Squib (BMS) recently discovered a CXCR4-specific monoclonal antibody (BMS-93654) that induces apoptosis in several CXCR4+ tumor models including AML, NHL, and multiple myeloma [43]. Here, CXCR4 is linked to non-Hodgkin lymphoma.